All treatments
Stem Cell & Regenerative
iPSC-Derived CAR-T (iCART)
Nobel-winning iPSC technology — CiRA Kyoto & Takeda
iPSC-Derived CAR-T (iCART)
Standardized CAR-T cells produced from a single iPSC cell line are ready as an 'off-the-sh…
How does it work?
Standardized CAR-T cells produced from a single iPSC cell line are ready as an 'off-the-shelf' product without waiting for donor or patient cells. This platform, developed by CiRA Kyoto and Takeda, aims to eliminate waiting time.
- Ready off-the-shelf cells
- Kyoto CiRA + Takeda collaboration
- Japan granted first iPSC approvals in 2026
Who is it for?
- Patients needing urgent treatment who cannot wait for cell manufacturing
- Those whose own T cells are insufficient
- B-cell lymphoma focused programs
B-cell LymphomaBlood Cancers
Treatment course
Varies by program phase; a clear timeline is shared after evaluation.
After treatment
Close follow-up per clinical program protocol; a control plan is made together in Türkiye.